![Jean Fan](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jean Fan
Technik-/Wissenschafts-/F&E-Leiter bei
NEOIMMUNETECH, INC.
Profil
Jean Fan currently works at TransThera Sciences (Nanjing), Inc., as Chief Medical Officer from 2022 and NeoImmuneTech, Inc., as Chief Clinical Officer from 2021.
Dr. Fan also formerly worked at Blueprint Medicines Corp., as Vice President-Clinical Development.
Aktive Positionen von Jean Fan
| Unternehmen | Position | Beginn |
|---|---|---|
| NEOIMMUNETECH, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2020 |
| TRANSTHERA SCIENCES (NANJING), INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.11.2022 |
Ehemalige bekannte Positionen von Jean Fan
| Unternehmen | Position | Ende |
|---|---|---|
| BLUEPRINT MEDICINES CORPORATION | Technik-/Wissenschafts-/F&E-Leiter | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
34
Beziehungen ersten Grades
3
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Blueprint Medicines Corp.
 Blueprint Medicines Corp. BiotechnologyHealth Technology Develops cancer therapies that harness the growing understanding of the molecular blueprint of cancer | Health Technology |
NeoImmuneTech, Inc.
 NeoImmuneTech, Inc. BiotechnologyHealth Technology Develops novel immuno-therapeutics | Health Technology |
TransThera Sciences (Nanjing), Inc.
 TransThera Sciences (Nanjing), Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company focusing on discovering and developing small molecule therapies | Health Technology |
